Consumer interest in immunity is at an all-time high. FrieslandCampina shares that in 2020, the number of consumers that actively wanted to improve their immunity rose from 50% to 70%; 60% said they have become more conscious about their immune health as a result of COVID-19.[1] At the same time, people are more interested in, and are educating themselves about, ingredients that are scientifically proven to support immune health, including those derived from dairy. Consumers are proactively seeking solutions which contain scientifically proven ingredients with supporting clinical evidence that demonstrate they can help support the human body against disease and illness.
FrieslandCampina Ingredients aims to help brand owners that want to tap into this growing market opportunity. The company has developed two new consumer application suggestions as part of the BiotisTM Immune Health solutions range, based on its well-researched BiotisTM lactoferrin: Immunity Up! chewable gummies and its Immune-Plus powder drink.
“Our BiotisTM Health Benefit Solutions represent a new era of ingredient science,” says Guus Aerts, Managing Director for Performance, Active and Medical Nutrition at FrieslandCampina Ingredients. “Supporting immune health has been a growing top priority for consumers for some time, and of course the global COVID-19 pandemic has continued to ensure that immunity stays in the spotlight. Through our BiotisTM brand, we bring together renowned scientific understanding, extensive application expertise and global market insights to unlock new opportunities for our customers in the health and wellness field. With dairy and immunity going hand in hand, we’re very excited to be expanding our BiotisTM portfolio with concepts that will support immune health using natural, science-backed ingredients.”
Lactoferrin, a protein naturally present in cow and human milk, is proven to provide multiple immune health benefits in adults. FrieslandCampina Ingredients is set to be one of the world’s largest suppliers of this valuable and versatile ingredient by 2022.
Miriam Peters, Marketing Manager at BiotisTM Immune Health adds, “It’s certainly important that new products appeal to consumer health concerns and fit into their daily lifestyles. But it is also essential that products are effective. Lactoferrin is a protein naturally present in cow and human milk. It is proven to provide multiple immune health benefits in adults, including reducing the risk of both viral[2],[3],[4] and bacteriological[5],[6],[7],[8] infections, and of iron deficiency[9],[10],[11] which can affect the body’s defences. With the expansion currently in progress, FrieslandCampina Ingredients is set to be one of the world’s largest suppliers of this valuable and versatile ingredient by 2022.
“With BiotisTM Immune Health, we remain at the forefront of rapidly evolving science and innovation in this field – committed to furthering our scientific knowledge of lactoferrin and other promising dairy ingredients – in order to collaborate with customers to bring effective immunity solutions to the market.”
As well as delivering tangible immune health benefits, FrieslandCampina Ingredients’ BiotisTM lactoferrin features the highest and most consistent quality level on the global market. This is achieved through FrieslandCampina Ingredients’ total control of each part of the lactoferrin supply chain, starting from the production of the raw milk and including the precise heat treatment process that preserves nativity and bioactivity.
“Though the pandemic may have boosted innovation in the immunity space, we see immune-targeted solutions playing an important role in consumers’ lives now and in the years to come, as individuals look to futureproof themselves against further potential health threats,” continues Aerts. “With this in mind, we’re really looking forward to continued collaboration with our customers to bring these much-needed solutions to life.”
[1] FMCG Gurus, 2020
[2] Vitetta, L. et al., 2013
[3] Oda et al., 2020
[4] Campione et al., 2020
[5] Laffan, A. M. et al., 2011
[6] Guntapalli et al., 2013
[7] De Bortoli et al., 2007
[8] Okuda et al., 2005
[9] Koikawa N et al., 2008
[10] Maccio et al., 2010
[11] Paesano et al., 2010